Evolus (EOLS) PT Set at $31.00 by Mizuho

Share on StockTwits

Evolus (NASDAQ:EOLS) has been given a $31.00 price objective by analysts at Mizuho in a note issued to investors on Monday, TipRanks reports. The firm currently has a “buy” rating on the stock. Mizuho’s target price would indicate a potential upside of 78.37% from the stock’s current price.

A number of other research analysts have also weighed in on EOLS. Zacks Investment Research lowered shares of Evolus from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. Stifel Nicolaus initiated coverage on shares of Evolus in a research note on Monday, January 28th. They issued a “buy” rating and a $27.00 price objective for the company. HC Wainwright initiated coverage on shares of Evolus in a research note on Thursday, February 14th. They issued a “buy” rating and a $37.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research note on Tuesday, March 19th. Finally, SunTrust Banks initiated coverage on shares of Evolus in a research note on Wednesday, March 20th. They issued a “buy” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Evolus currently has an average rating of “Buy” and a consensus target price of $31.00.

Shares of EOLS stock traded up $1.28 during trading hours on Monday, hitting $17.38. 1,514,300 shares of the company were exchanged, compared to its average volume of 1,060,346. The company has a quick ratio of 14.52, a current ratio of 14.80 and a debt-to-equity ratio of 0.96. Evolus has a 52-week low of $10.22 and a 52-week high of $39.50. The firm has a market cap of $440.06 million, a P/E ratio of -11.07 and a beta of 5.01.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Tuesday, April 30th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.11). As a group, equities analysts expect that Evolus will post -3.06 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in EOLS. BlackRock Inc. grew its stake in Evolus by 51.6% in the 4th quarter. BlackRock Inc. now owns 933,601 shares of the company’s stock valued at $11,110,000 after buying an additional 317,882 shares in the last quarter. Vanguard Group Inc boosted its holdings in Evolus by 87.1% in the 3rd quarter. Vanguard Group Inc now owns 406,549 shares of the company’s stock valued at $7,570,000 after purchasing an additional 189,277 shares during the period. Vanguard Group Inc. boosted its holdings in Evolus by 87.1% in the 3rd quarter. Vanguard Group Inc. now owns 406,549 shares of the company’s stock valued at $7,570,000 after purchasing an additional 189,277 shares during the period. Morgan Stanley boosted its holdings in Evolus by 239.8% in the 1st quarter. Morgan Stanley now owns 201,708 shares of the company’s stock valued at $4,552,000 after purchasing an additional 142,351 shares during the period. Finally, Advisor Group Inc. boosted its holdings in Evolus by 9,865.8% in the 4th quarter. Advisor Group Inc. now owns 129,556 shares of the company’s stock valued at $1,542,000 after purchasing an additional 128,256 shares during the period. Institutional investors and hedge funds own 19.33% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

See Also: What is a Fibonacci Channel?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stock Traders Buy Large Volume of Boingo Wireless Call Options
Stock Traders Buy Large Volume of Boingo Wireless Call Options
Texas Roadhouse Sees Unusually Large Options Volume
Texas Roadhouse Sees Unusually Large Options Volume
Diebold Nixdorf Inc  Receives $6.00 Consensus Price Target from Brokerages
Diebold Nixdorf Inc Receives $6.00 Consensus Price Target from Brokerages
PennyMac Mortgage Investment Trust  Declares $0.47 Quarterly Dividend
PennyMac Mortgage Investment Trust Declares $0.47 Quarterly Dividend
WillScot Corp  Receives $16.79 Average Target Price from Brokerages
WillScot Corp Receives $16.79 Average Target Price from Brokerages
Jay T. Scripter Sells 25,758 Shares of Trex Company Inc  Stock
Jay T. Scripter Sells 25,758 Shares of Trex Company Inc Stock


© 2006-2019 Ticker Report